The revenue of the dermatological drugs market in 2018 is estimated at $31bn and is expected to grow at a CAGR of 3.7% in the first half of the forecast period. Psoriasis drugs segment accounted for the largest share of the market in 2018, this segment accounted for 38% of the global dermatological drugs market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 355-page report you will receive 133 tables and 154 figures– all unavailable elsewhere.
The 355-page report provides clear detailed insight into the dermatological drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Dermatological drugs market forecasts from 2020-2030
• This report also breaks down the revenue forecast for the main submarkets:
• Psoriasis
• Skin Infections
• Acne
• Dermatitis
• Analysis of the Psoriasis drugs market. Revenue forecasts to 2030 are provided for the following drugs:
• Humira
• Stelara
• Enbrel
• Remicade
• Taltz
• Otezla
• Cosentyx
• Analysis of the Skin Infections drugs market. Revenue forecasts to 2030 are provided for the following drugs:
• Cubicin
• Zyvox
• Valtrex
• Canesten
• Lamisil
• Bactroban
• Analysis of the Acne drugs market. Revenue forecasts to 2030 are provided for the following drugs:
• Solodyn
• Epiduo
• Claravis
• Aczone
• Differin
• Abscorical/Epirus
• Ziana
• Doryx
• Analysis of the Dermatitis drugs market. Revenue forecasts to 2030 are provided for the following drugs:
• Bepanthen/Bepanthol
• Protopic
• Dermovate
• Elocon
• This report provides individual revenue forecasts to 2030 for these regional and national markets:
• North America: US & Canada
• Europe: Germany, France, UK, Italy, Spain, Rest of Europe
• Asia-Pacific: China, Japan, India, Rest of Asia-Pacific
• Latin America: Brazil, Mexico, Rest of Latin America
• Middle East & Africa (MEA): Saudi Arabia, South Africa, Rest of MEA
Each regional market is further segmented by indication: psoriasis, skin infection, acne, dermatitis and others.
• This report provides discussion on pipeline products in various stages of clinical trials and regulatory approval.
• Our study includes SWOT analysis and Porter’s Five Force analysis of the dermatological drugs market.
• Our study discusses the selected leading companies that are the major players in the dermatological drugs market:
• AbbVie
• Allergan
• Amgen
• Bausch Health
• Bayer AG
• Bristol-Myers Squibb
• Celgene Corporation
• Eli Lilly
• Galderma (Nestle Skin Health S.A.)
• GlaxoSmithKline (GSK)
• Johnson & Johnson
• LEO Pharma
• Merck & Co, Inc.
• Novartis
• Pfizer
• Key questions answered by this report:
• How is the dermatological drugs market evolving?
• What is driving and restraining the dermatological drugs market?
• What are the market shares of each segment of the overall dermatological drugs market in 2019?
• How will each dermatological drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2030?
• How will the market shares for each dermatological drugs submarket develop from 2020 to 2030?
• Which individual therapies will prevail and how will these shifts be responded to?
• What will be the main driver for the overall market from 2020 to 2030?
• How will political and regulatory factors influence the regional markets and submarkets?
• Will leading national dermatological drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2030 and which geographical region will lead the market in 2030?
• Who are the leading players and what are their prospects over the forecast period?
• How will the industry evolve during the period between 2019 and 2030?
• Visiongain understands that the dermatological drugs market will register strong growth. This report examines in detail the market by region, by submarket, and as a whole, and provides the reader with a thorough overview of the market to identify key growth areas and business opportunities to exploit. This is where Visiongain adds value.
Visiongain’s study is intended for anyone requiring commercial analyses for the dermatological drugs market. You find data, trends and predictions.
Buy our report today Dermatological Drugs Market Forecast 2020-2030: Psoriasis, Skin Infection, Acne, Dermatitis, Others.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1 Global Dermatological Drugs Market Overview
1.2 Overview of Findings
1.3 Structure of the Report
1.4 Global Dermatological Drugs Market Segmentation
1.5 Why You Should Read This Report
1.6 How This Report Delivers
1.7 Key Questions Answered by This Analytical Report
1.8. Who is This Report For?
1.9 Methodology
1.10 Associated Visiongain Reports
1.11 About Visiongain
2. Introduction to Dermatological Drugs
2.1 The Pharmaceutical Industry: A Brief Introduction
2.2 An Introduction to Dermatology
2.2.1 The Structure of Skin, Hair, and Nails
2.2.2 Hair and Nails
2.2.3 Sweat and Sebaceous Glands
2.2.4 Functions of the Skin
2.3 Common Skin Diseases
2.3.1 Acne: The Most Common Skin Disease
2.3.1.1 Acne: Epidemiology
2.3.1.2 Acne: Causes and Pathogenesis
2.3.1.3 Acne: Treatment
2.3.2 Dermatitis: Inflammation of the Skin
2.3.2.1 Atopic Dermatitis
2.3.2.2 Contact Dermatitis
2.3.2.3 Seborrhoeic Dermatitis
2.3.2.4 Nummular Dermatitis
2.3.2.5 Perioral Dermatitis
2.3.3 Psoriasis: A Complex Multi-Factorial Disease
2.3.4 Rosacea: Vascular Instability
2.3.5 Alopecia: Excessive Shedding of Hair
2.4 Skin Infections: A Serious Healthcare Threat
2.4.1 Bacterial Skin Infections
2.4.2 Fungal Skin Infections
2.4.3 Viral Skin Infections
2.5 Common Skin Treatments
2.5.1 Creams and Semisolid Emulsions
2.5.2 Ointments
2.5.3 Lotions
2.5.4 Solutions
2.5.5 Occlusive Therapy
2.5.6 Cleansing Agents
2.5.7 Powders and Hydrophilic Polymer
2.5.8 Anti-Infective Agents
2.5.9 Anti-Inflammatory Agents
2.6 Phases of Clinical Trials
2.7 Dermatological Drugs: Market Definition in this Report
3. Global Dermatological Drugs Market by Indication 2020-2030
3.1 The Global Dermatological Drugs Market: Market Overview
3.2 Categorisation of the Global Dermatological Drugs Market
3.3 The Global Dermatological Drugs Market in 2019
3.4 The Global Dermatological Drugs Market: Market Forecast 2020-2030
3.5 Changing Market Shares by Segment 2020-2030
4. The Psoriasis Drugs Market: Market Analysis and Forecast 2020-2030
4.1 Psoriasis Treatments: The Dominance of Biologics
4.1.1 Leading Products in the Psoriasis Drugs Market, 2019
4.2 Psoriasis: Market Trends and Developments, 2019
4.2.1 Biological Drugs in Psoriasis Treatment: A Brief Overview
4.2.2 Issues around Patent Protection, the Threat of Biosimilars and Pricing
4.2.3 Biosimilars and Interchangeables
4.2.3.1 Extrapolation of indications
4.2.3.2 Biosimilar interchangeability in the EU
4.2.3.3 Biosimilar guidance in the US
4.2.3.4 The Disadvantages of Biologics in Psoriasis Treatment
4.3 Psoriasis Drugs: Market Forecast 2020-2030
4.3.1 Psoriasis Drugs: Changing Market Shares by Leading Drugs 2020-2030
4.4 Leading Drugs Used in the Treatment of Psoriasis
4.4.1 Humira (adalimumab) - AbbVie
4.4.1.1 Humira: Historical Sales Analysis, 2010-2017
4.4.1.2 Humira: Sales Forecast 2020-2030
4.4.1.3 Future Prospects for Biosimilar Versions of Humira
4.4.2 Stelara (ustekinumab) – Johnson & Johnson
4.4.2.1 Stelara New Market Leader, Ahead of Humira
4.4.2.2 Stelara: Historical Sales Analysis, 2010-2017
4.4.2.3 Stelara: Sales Forecast 2020-2030
4.4.2.4 Intensifying Competition for Stelara
4.4.3 Enbrel (etanercept) - Amgen/ Pfizer/ Takeda
4.4.3.1 Enbrel: Co-Promotions and Marketing Rights
4.4.3.2 Enbrel: Historical Sales Analysis, 2009-2017
4.4.3.3 Enbrel: Patent Expiries and Potential Competition, 2020-2030
4.4.3.4 Patent Litigation with Sandoz Over Enbrel
4.4.3.5 Enbrel: Sales Forecast 2020-2030
4.4.3.6 Enbrel Auto-injector Pens: A Driver of Growth in Recent Years
4.4.3.7 Competition from Other Drugs
4.4.3.8 Biosimilar Competition for Enbrel
4.4.4 Remicade (infliximab) – Johnson & Johnson
4.4.4.1 Remicade: Historical Sales Analysis, 2009-2017
4.4.4.2 Remicade: Patent Expiries and Potential Competition, 2020-2030
4.4.4.3 Remicade: Sales Forecast 2020-2030
4.4.5 Taltz (ixekizumab) – Eli Lilly
4.4.5.1 Taltz: Sales Forecast 2020-2030
4.4.6 Otezla (apremilast) – Celgene
4.4.6.1 Otezla: Sales Forecast 2020-2030
4.4.7 Cosentyx (secukinumab) - Novartis
4.4.7.1 Cosentyx: Sales Forecast 2020-2030
4.4.8 Other Psoriasis Drugs
4.4.8.1 Cimzia (certolizumab) - UCB
4.4.8.2 Sorilux (calcipotriene foam) - GSK
4.4.8.3 Siliq (brodalumab) - AstraZeneca/ LEO Pharma
4.4.8.4 Other Psoriasis Drugs: Sales Forecast 2020-2030
4.5 Psoriasis Drugs Market: Summary
5. Skin Infection Drugs Market: Market Analysis and Forecast 2020-2030
5.1 Skin Infection Drugs: Abundant Growth Opportunities
5.1.1 Leading Products in the Skin Infection Drugs Market, 2019
5.2 Skin Infection Drugs: Market Forecast 2020-2030
5.2.1 Skin Infection: Changing Market Shares by Leading Drugs 2020-2030
5.3 Leading Drugs Used in the Treatment of Skin Infections
5.3.1 Cubicin (daptomycin) - Cubist Pharmaceuticals/ Merck & Co
5.3.2 Acquisition by Merck & Co
5.3.3 Generic Competition for Cubicin
5.3.4 Cubicin: Sales Forecast 2020-2030
5.3.5 Lifecycle Management Strategies for Cubicin
5.4 Zyvox (linezolid) - Pfizer
5.4.1 Zyvox: Historical Sales Analysis, 2010-2017
5.4.2 Zyvox: Sales Forecast 2020-2030
5.4.3 The Threats to Zyvox Sales from Competing New Drugs
5.5 Canesten (clotrimazole) - Bayer
5.5.1 Canesten: Historical Sales Analysis, 2011-2017
5.5.2 Canesten: Sales Forecast 2020-2030
5.6 Valtrex (valaciclovir) - GSK
5.6.1 Valtrex: Historical Sales Analysis, 2010-2017
5.6.2 Valtrex: Sales Forecast 2020-2030
5.7 Sivexto
5.7.1 Sivexto: Sales Forecast 2020-2030
5.8 Lamisil (terbinafine) - Novartis
5.8.1 Lamisil Patent Expiry
5.8.2 Lamisil Sales Affected by Novartis Manufacturing Problems
5.8.3 Lamisil: Sales Forecast 2020-2030
5.9 Other Skin Infection Drugs
5.9.1 Dalvance (dalbavancin) - Durata Therapeutics
5.9.2 Jublia (efinaconazole) - Valeant
5.9.3 Kerydin (tavaborole) - Anacor
5.9.4 Zovirax (acyclovir) - Valeant/GSK
5.9.4.1 Valeant Acquires Zovirax in US and Canada
5.9.4.2 Mylan‟s Generic Zovirax and Actavis‟ Authorised Generic
5.9.5 Other Skin Infection Drugs: Sales Forecast 2020-2030
5.10 Skin Infection Drugs: Market Summary
6. Acne Drugs Market: Market Analysis and Forecast 2020-2030
6.1 Acne Drugs: A Diversified Market
6.1.1 Leading Products in the Acne Drugs Market, 2019
6.2 Acne Drugs Market: Recent Trends and Developments
6.2.1 The Rise of Combination Therapies in Acne Treatment
6.2.2 Oral Contraceptives in Treating Acne
6.2.3 The Threat of Generic Competition in the Acne Drugs Market
6.3 Acne Drugs: Market Forecast 2020-2030
6.3.1 Acne Drugs: Changing Market Shares by Leading Drugs 2020-2030
6.4 Leading Drugs in the Acne Drugs Market
6.4.1 Epiduo (adapalene/benzoyl peroxide) – Galderma/ Nestlé Skin Health
6.4.1.1 Epiduo: Sales Forecast 2020-2030
6.4.1.2 Galderma Settlement Agreement over Generic Epiduo
6.4.1.3 Paediatric Approval for Epiduo
6.4.2 Solodyn (minocycline) - Valeant
6.4.2.1 Solodyn: Sales Forecast 2020-2030
6.4.2.2 Antitrust Action over Solodyn Pay-For-Delay Deals
6.4.2.3 Impax and Medicis Collaborating on Advanced Solodyn
6.4.2.4 Medicis and Lupin Settle
6.4.3 Claravis (isotretinoin) - Teva
6.4.3.1 Claravis: Sales Forecast 2020-2030
6.4.4 Aczone (dapsone) - Allergan
6.4.4.1 Aczone: Sales Forecast 2020-2030
6.4.5 Retin-A Micro – Bausch Health
6.4.5.1 Retin-A Micro: Sales Forecast 2020-2030
6.4.6 Absorica/Epuris (CIP-isotretinoin) – Cipher/Sun Pharma
6.4.6.1 Absorica/Epuris: Sales Forecast 2020-2030
6.4.7 Ziana (clindamycin/tretinoin) – Valeant Pharmaceuticals International
6.4.7.1 Valeant‟s Patent Settlement with Actavis over Ziana
6.4.7.2 Ziana: Sales Forecast 2020-2030
6.4.8 Acanya (clindamycin/benzoyl peroxide) – Dow /Valeant
6.4.8.1. Actavis Claims First-to-File Exclusivity for its Acanya
6.4.8.2 Legal Battles Involving Dow/Valeant, Perrigo, and
6.4.8.3 Acanya: Sales Forecast 2020-2030
6.4.9 Other Acne Drugs
6.4.9.1 Doryx (doxycycline) – Actavis/Mayne Pharma
6.4.9.1.1 Lifecycle Management Strategies for Doryx
6.4.9.1.2 Divestment Agreement with Mayne Pharma
6.4.9.1.3 Generic Competition for Doryx
6.4.9.2 Amnesteem (isotretinoin) - Mylan
6.4.9.2.1 Amnesteem: Financial Analysis
6.4.9.3 Diane (cyproterone/ethinyl estradiol) - Bayer
6.4.9.4 Duac (clindamycin/benzoyl peroxide) –
6.4.9.5 Veltin (tretinoin/clindamycin) - GSK
6.4.9.6 Other Acne Drugs: Sales Forecast 2020-2030
6.5 Acne Drugs: Market Summary
7. Dermatitis Drugs Market: Market Analysis and Forecast 2020-2030
7.1 Dermatitis Drugs: High Generic Penetration
7.1.1 Leading Products in the Dermatitis Drugs Market, 2019
7.2 Dermatitis Drugs: Market Forecast 2020-2030
7.2.1 Dermatitis Drugs: Changing Market Shares by Leading Drugs 2020-2030
7.3 Leading Drugs in the Dermatitis Drugs Market
7.3.1 Bepanthen (dexpanthenol)/ Bepanthol - Bayer
7.3.1.1 Bepanthen: Sales Forecast 2020-2030
7.3.2 Elocon (mometasone) - Merck & Co
7.3.2.1 Elocon: Sales Forecast 2020-2030
7.3.3 Protopic (tacrolimus) – LEO Pharma
7.3.3.1 Protopic Benefits from Expanded Indication
7.3.3.2 Generic Competition for Protopic
7.3.3.3 Protopic: Sales Forecast 2020-2030
7.3.4 Dermovate -GSK
7.3.4.1 Dermovate: Sales Forecast 2020-2030
7.3.5 Other Dermatitis Drugs: Sales Forecast 2020-2030
7.4 Dermatitis Drugs: Market Outlook
8. Leading National Markets 2020-2030
8.1. Geographical Breakdown of the World Dermatological Drugs Market
8.2 World Dermatological Drugs Market: Regional Forecast 2020-2030
8.2.1 How Will Regional Market Shares Change to 2030?
9. North America Dermatological Drugs Market 2020-2030
9.1. U.S. Dermatological Drugs Market: Trends and Developments
9.1.1. Obamacare Repeal
9.1.2. Legislative Environment Stimulating Biosimilars
9.1.3 Biosimilar Interchangeability guidance in the US
9.1.4 US Dermatological Drugs Market: Market Forecast 2020-2030
9.2. Canada Dermatological Drugs Market: Trends and Developments
10. Europe Dermatological Drugs Market 2020-2030
10.1 Europe Markets: Changing Market Shares by Country, 2020-2030
10.2 Germany
10.2.1 Germany Dermatological Drugs Market: Market Forecast 2020-2030
10.3. France Dermatological Drugs Market Forecast 2020-2030
10.4. U.K.
10.4.1 The Impact of Brexit On the Dermatological Drugs
10.4.2 Pricing and Reimbursement
10.4.3 New Regulatory Body and Clinical Trials
10.4.4 Patent Protection
10.4.5 Research and Funding
10.4.6. U.K. Dermatological Drugs Market Forecast 2020-2030
10.5 Italy
10.5.1 Italy Dermatological Drugs Market Forecast 2020-2030
10.6. Spain Dermatological Drugs Market Forecast 2020-2030
10.7. Rest of Europe Dermatological Drugs Market Forecast 2020-2030
10.7.1 Russia
10.7.1.1 Pharma2020 Strategy - Healthcare and Industry Reform
11. Asia-Pacific Dermatological Drugs Market 2020-2030
11.1 China
11.1.1 Expansion of Healthcare Coverage and Reimbursement in China
11.1.2 Improving Public Perception of Dermatology in China
11.1.3 Price Controls and the Anhui Model
11.1.4 Chinese Dermatological Drugs Market Forecast 2020-2030
11.2. Japan Dermatological Drugs Market: Trends and Developments
11.2.1 The Cost of Treatment in Japan
11.2.2 Japanese Pharmaceutical Industry Regulatory Reform
11.2.3 Japanese Dermatological Drugs Market Forecast 2020-2030
11.3. India
11.3.1 The Effects of the Drug Prices Control Order of 2013
11.3.2 India‟s Expansion of Healthcare Provision
11.3.3 Revised Biosimilar Guidelines
11.3.4 Indian Dermatological Drugs Market Forecast 2020-2030
11.4. Rest of Asia-Pacific Dermatological Drugs Market: Trends and Developments
12. Latin America Dermatological Drugs Market 2020-2030
12.1 Brazil
12.1.1 The Growth in Brazil‟s Healthcare Landscape
12.1.2 Clearer Access to Medicines in Brazil
12.1.3 Brazil Dermatological Drugs Market Forecast 2020-2030
12.2. Mexico Dermatological Drugs Market: Trends and
12.3. Rest of Latin America Dermatological Drugs Market: Trends and Developments
13. Middle East & Africa Dermatological Drugs Market 2020-2030
13.1. Saudi Arabia Dermatological Drugs Market Forecast 2020-2030
13.2. South Africa Dermatological Drugs Market Forecast 2020-2030
13.3. Rest of Middle East & Africa Dermatological Drugs Market Forecast 2020-2030
14. Leading Companies in the Dermatological Drugs Market
14.1. Galderma (Nestle Skin Health S.A.)
14.1.1 Galderma: Dermatological Drugs Product Portfolio
14.1.2 Financial Overview
14.1.3. Recent Transactions Summary
14.2. Johnson & Johnson
14.2.1. Johnson & Johnson: Dermatological Drugs Product Portfolio
14.2.2 Financial Overview
14.2.2.1 Pipeline, 2019
14.2.3. Recent Transactions Summary
14.3. GlaxoSmithKline plc
14.3.1 GlaxoSmithKline plc: Dermatological Drugs Portfolio
14.3.2 GlaxoSmithKline plc: Financial Overview
14.3.3 GlaxoSmithKline plc: Recent Transactions Summary
14.4. Pfizer, Inc.
14.4.1 Pfizer, Inc.: Dermatological Drugs Portfolio
14.4.2 Pfizer, Inc.: Financial Overview
14.4.3 Pfizer, Inc.: Recent Developments
14.4.4 Pfizer: Dermatological Drugs Development Pipeline, 2019
14.5.LEO Pharma A/S
14.5.1 LEO Pharma A/S.: Dermatological Drugs Product Portfolio
14.5.2 Financial Overview
14.5.3 Recent Transactions Summary
14.6. AbbVie Inc.
14.6.1 AbbVie Inc.: Dermatological Drugs Product Portfolio
14.6.2 Financial Overview
14.6.3 Recent Transactions Summary
14.7. Novartis AG
14.7.1 Novartis: Dermatological Drugs Portfolio
14.7.2 Novartis: Financial Overview
14.7.3 Novartis: Recent Developments
14.8. Amgen, Inc.
14.8.1 Amgen, Inc.: Dermatological drugs Portfolio
14.8.2 Financial Overview
14.8.3. Recent Transactions Summary
14.9. Merck & Co., Inc.
14.9.1 Merck & Co., Inc.: Dermatological Drugs Portfolio
14.9.2 Merck & Co., Inc.: Financial Overview
14.9.3 Merck & Co., Inc.: Recent Transactions Summary
14.10. Bayer AG
14.10.1 Bayer AG: Dermatological Drugs Portfolio
14.10.2 Bayer AG: Financial Overview
14.10.3 Bayer AG: Recent Transactions Summary
14.11. Celgene Corporation
14.11.1 Celgene Corporation: Dermatological Drugs Product Portfolio
14.11.2 Celgene Corporation: Financial Overview
14.11.3 Celgene Corporation: Recent Transactions Summary
14.12. Bausch Health Companies Inc.
14.12.1 Bausch Health Companies Inc.: Dermatological Drugs Product Portfolio
14.12.2 Bausch Health Companies Inc.: Dermatological Drugs Product Pipeline
14.12.3 Bausch Health Companies Inc.: Financial Overview
14.12.4 Bausch Health Companies Inc.: Recent Developments
14.13. Bristol-Myers Squibb Company
14.13.1 Bristol-Myers Squibb Company: Dermatological Drugs Product Portfolio
14.13.2 Bristol-Myers Squibb Company: Dermatological Drugs Product Pipeline
14.13.3 Bristol-Myers Squibb Company: Financial Overview
14.13.4 Bristol-Myers Squibb Company: Recent Transactions Summary
14.14. Allergan plc
14.14.1 Allergan plc: Dermatological Drugs Product Portfolio
14.14.2 Allergan plc: Financial Overview
14.14.3 Allergan plc: Recent Transactions Summary
14.15. Eli Lilly and Company
14.15.1 Eli Lilly and Company: Dermatological Drugs Product Portfolio
14.15.2 Eli Lilly and Company: Financial Overview
14.15.3 Eli Lilly and Company: Recent Transactions Summary
15. Dermatological Drugs: Research and Development Pipeline, 2020-2030
15.1 Innovative Products Currently in Development Will Drive Growth
15.1.1 New Technology in R&D Pipeline Activities
15.1.1.1 Reformulation
15.1.1.2 Combination Treatments
15.1.1.3 New Mechanisms and Drug Delivery Technologies
15.1.1.4 Potential Market Entrants
15.2 Psoriasis Drugs Development Pipeline, 2019
15.2.1 Psoriasis Drugs in Phase 3 Development or
15.2.1.2 CF101 (Piclidenoson) - Can-Fite BioPharma
15.2.2 Psoriasis Drugs in Phase 2 Development
15.2.2.1 LY3009104 (baricitinib) - Incyte/ Eli Lilly
15.2.2.2 PH-10 (Rose Bengal) – Provectus
15.2.3 Psoriasis Drugs in Phase 1 and Pre-Clinical
15.3 Skin Infection Drugs Development Pipeline, 2019
15.3.1 Drugs in Phase 3 Development for Skin Infections
15.3.1.1 Baxdela (delafloxacin) - Melinta Pharmaceuticals
15.3.1.2 NB-001 - NanoBio Corporation
15.3.1.3 Luliconazole - Topica Pharmaceuticals
15.3.2 Drugs in Phase 2 Development for Skin Infections
15.3.3 Drugs in Phase 1 and Preclinical Pipeline for Skin Infections
15.4 Acne Drugs Development Pipeline, 2019
15.4.1 Drugs in Phase 3 Development for Acne
15.4.1.2 Visonac (photodynamic therapy) - Photocure
15.4.2 Drugs in Phase 2 Development for Acne
15.4.3 Drugs in Phase 1 and Pre-Clinical Development for Acne
15.4.4 A Possible Vaccine for Acne
15.5 Dermatitis Drugs Development Pipeline, 2019
15.5.1 Drugs in Phase 3 Development for Dermatitis
15.5.1.1 Toctino (alitretinoin) - GSK
15.5.1.2 Dermadexin and Pruridexin (P3CGM) – Cipher
15.5.1.3 Dexeryl Cream (glycerol/paraffin emollient) – Pierre
15.5.1.4 REGN668/SAR231893 (dupilumab) -
15.5.2 Drugs in Phase 2 Development for Dermatitis
15.5.3 Drugs in Phase 1 and Preclinical Stages of Development for Dermatitis
15.6 Other Dermatological Drugs Development Pipeline, 2019
15.6.1 Other Dermatological Drugs: Filed or Recently
15.6.1.1 Actikerall (fluorouracil/salicylic acid) - Almirall
15.6.1.2 Ameluz (5-ALA photodynamic therapy) - Biofrontera
15.6.1.3 Mirvaso (brimonidine) - Galderma
15.6.1.4 Picato (ingenol mebutate) - LEO Pharma
15.6.1.5 Xolair (omalizumab) - Novartis/ Roche
15.6.2 Other Dermatological Drugs: Phase 3 Pipeline
15.6.2.1 CD5024 (ivermectin) - Galderma
15.6.2.2 SR-T100 gel (Solanum incanum extract) - G&E
15.6.3 Other Dermatological Drugs: Phase 2 Pipeline
16. Qualitative Analysis of the Dermatological Drugs Market, 2020-2030
16.1 Market Factors Influencing Dermatological Drugs
16.2 SWOT Analysis of the Global Dermatological Drugs Market, 2020-2030
16.2.1 Strengths
16.2.1.1 The High Unmet Clinical Need in Dermatology
16.2.1.2 A Healthy Pipeline of Development-Stage Products
16.2.1.3 Strong Industry-Physician Relationships
16.2.2 Weaknesses
16.2.2.1 Limited Efficacy and Adverse Effects May Impact
16.2.2.2 Patient Adherence – A Major Challenge to
16.2.2.3 Impending Patent Expiries and the Challenges
16.2.3 Opportunities
16.2.3.1 The High-Growth Sectors in Dermatology
16.2.3.2 Personalised Dermatology: Technological Advances in Genomics
16.2.3.3 Advances in Topical Drug Delivery Methods Offers
16.2.3.4 Consolidation within Dermatology – Opportunity for Synergistic Growth?
16.2.4 Threats
16.2.4.1 Uncertainty Surrounding Reimbursement and
16.2.4.2 The Rising Cost of Research and Development
16.2.4.3 Downward Pressures on Drug Prices
16.3 Porter‟s Five Force Analysis of the Global Dermatological Drugs Market, 2020-2030
16.3.1 Threat of New Entrants
16.3.2 Threat of Substitutes
16.3.3 Rivalry among Competitors
16.3.4 Power of Buyers
16.3.5 Power of Suppliers
17. Conclusions
17.1 Overview of Current Market Conditions and Market Forecast, 2020-2030
17.2 Leading Sectors in Dermatological Drugs in 2019
17.3 Leading Regions in the Dermatological Drugs Market in 2019
17.4 Future Outlook for the Various Sectors within the Dermatological Drugs Market, 2020-2030
17.5 What Does the Future Hold for Dermatological Drugs?
Appendices
Associated Visiongain Reports
Global OTC Pharmaceutical Market Forecast 2020-2030
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Tables
Table 2.1 Clinical Trial Phases, 2019
Table 3.1 Global Dermatological Drugs Market Indication: Revenue ($bn), and Market Share (%), 2019
Table 3.2 Global Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
Table 3.3 Global Dermatological Drugs Market Indication: CAGR (%), 2020-2025, 2025-2030, 2020-2030
Table 4.1 Global Psoriasis Drugs Market by Drugs: Revenue ($bn), and Market Share (%), 2019
Table 4.2 Global Psoriasis Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
Table 4.3 Global Psoriasis Drugs Market by Drugs: Market Share (%), 2020-2025, 2025-2030, 2020-2030
Table 4.4 Global Humira Market Forecast: Revenues ($bn) AGR (%), 2010-2017
Table 4.5 Global Humira Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
Table 4.6 Global Stelara Market Forecast: Revenues ($bn) AGR (%), 2010-2017
Table 4.7 Global Stelara Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
Table 4.8 Global Enbrel Market Forecast: Revenues ($Bn) AGR (%), 2009-2017
Table 4.9 Global Enbrel Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
Table 4.10 Global Remicade Market Forecast: Revenues ($bn) AGR (%), 2009-2017
Table 4.11 Global Remicade Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
Table 4.12 Global Taltz Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
Table 4.13 Global Otezla Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
Table 4.14 Global Cosentyx Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
Table 4.15 Global Others Market Forecast: Revenues ($Bn) AGR (%), CAGR (%), 2019-2030
Table 5.1 Global Skin Infection Drugs Market by Drugs: Revenue ($bn), and Market Share (%), 2019
Table 5.2 Skin Infection Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
Table 5.3 Global Skin Infection Drugs Market by Drugs: Market Share (%), 2019, 2025, & 2030
Table 5.4 Global Cubicin Market Forecast: Revenue ($bn) AGR & CAGR (%), 2019-2030
Table 5.5 Global Zyvox Market Forecast: Revenues ($bn) AGR (%), 2010-2017
Table 5.6 Global Zyvox Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
Table 5.7 Global Canesten Market Forecast: Revenues ($bn) AGR (%), 2011-2017
Table 5.8 Global Canesten Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
Table 5.9: Global Valtrex Market Forecast: Revenues ($bn) AGR (%), 2010-2017
Table 5.10 Global Valtrex Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
Table 5.11 Global Sivexto Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
Table 5.12 Global Lamisil Market Forecast: Revenues ($Bn) AGR (%), CAGR (%), 2019-2030
Table 5.13 Global Others Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
Table 6.1 Global Acne Drugs Market by Drugs: Revenue ($bn), and Market Share (%), 2019
Table 6.2 Global Acne Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
Table 6.3 Global Acne Drugs Market by Drugs: Market Share (%), 2019, 2025, 2030
Table 6.4 Global Epiduo Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
Table 6.5 Global Solodyn Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
Table 6.6 Global Claravis Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
Table 6.7 Global Aczone Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
Table 6.8 Global Retin-A Micro Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
Table 6.9 Global Absorica/ Epirus Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
Table 6.10 Global Ziana Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
Table 6.11 Global Acanya/Onexton Market Forecast: Revenues ($Bn) AGR (%), CAGR (%), 2019-2030
Table 6.12 Global Others Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
Table 7.1 Global Dermatitis Drugs Market by Drugs: Revenue ($bn), and Market Share (%), 2019
Table 7.2 Global Dermatitis Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
Table 7.3 Global Dermatitis Drugs Market by Drugs: Market Share (%), 2019, 2025, 2030
Table 7.4 Global Bepanthen/ Bepanthol Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
Table 7.5 Global Elocon Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
Table 7.6 Global Protopic Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
Table 7.7 Global Dermovate Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
Table 7.8 Others Dermatitis Drugs Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030
Table 8.1 Global Dermatological Drugs Market by Region: Revenue ($bn), 2019 and 2030
Table 8.2 Global Dermatological Drugs Market Forecast, by Region: Revenues ($ bn), AGR (%), CAGR (%), 2019-2030
Table 8.3 Global Dermatological Drugs Market by Region: Market Share (%), 2019, 2025, & 2030
Table 8.4 Global Dermatological Drugs Market by Region: Market Share (%), 2020, 2025, & 2030
Table 9.1 North America Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
Table 9.2 North America Dermatological Drugs Market Forecast, By Country: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
Table 9.3 U.S. Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
Table 9.4 Canada Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
Table 10.1 Global Dermatological Drugs Market by Country/Sub-region: Revenue ($bn) and Market Share (%), 2019
Table 10.2 Europe Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
Table 10.3 Europe Dermatological Drugs Market Forecast, By Country: Revenues ($ bn), AGR (%), CAGR (%), 2019-2030
Table 10.4 Europe Dermatological Drugs Market by Country/Sub-region: Market Share (%) 2019, 2025, & 2030
Table 10.5 Germany Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %)
Table 10.6 France Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
Table 10.7 U.K. Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %)
Table 10.8 Italy Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %)
Table 10.9 Spain Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %)
Table 10.10 Rest of Europe Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %)
Table 11.1 Asia-Pacific Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
Table 11.2 Asia-Pacific Dermatological Drugs Market Forecast, By Country: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
Table 11.3 China Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %)
Table 11.4 Japan Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %)
Table 11.5 India Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %)
Table 11.6 Rest of Asia-Pacific Dermatological Drugs Market Forecast, 2019-2030 ($ bn, AGR %, CAGR %)
Table 12.1 Latin America Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
Table 12.2 Latin America Dermatological Drugs Market Forecast, By Country: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
Table 12.3 Brazil Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %)
Table 12.4 Mexico Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %)
Table 12.5 Rest of Latin America Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %)
Table 13.1 Middle East & Africa (MEA) Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
Table 13.2 Middle East & Africa (MEA) Dermatological Drugs Market Forecast, By Country: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
Table 13.3 Saudi Arabia Dermatological Drugs Market Forecast, By Country: Revenues ($bn), AGR (%), CAGR (%), 2019-2030
Table 13.4 South Africa Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %)
Table 13.5 Rest of MEA Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %)
Table 14.1 Galderma: Overview, 2019
Table 14.2. Johnson & Johnson: Overview, 2019
Table 14.3 Johnson & Johnson: Revenue ($m), AGR (%), 2013-2017
Table 14.4 GlaxoSmithKline plc: Overview, 2019
Table 14.5 GlaxoSmithKline plc: Revenue ($m), 2014-2018
Table 14.6 GlaxoSmithKline: Dermatological Drugs Pipeline, 2019
Table 14.7 Pfizer, Inc.: Overview, 2019
Table 14.8 Pfizer, Inc.: Revenue ($m), 2015-2018
Table 14.9 LEO Pharma A/S: Overview, 2019
Table 14.10 LEO Pharma A/S: Revenue ($m), AGR (%), 2014-2018
Table 14.11 AbbVie Inc.: Overview, 2019
Table 14.12 AbbVie Inc.: Revenue ($m), AGR (%), 2014-2018
Table 14.13 Novartis: Overview, 2019
Table 14.14 Novartis: Revenue ($m), AGR (%), 2014-2018
Table 14.15 Amgen, Inc.: Overview, 2019
Table 14.16 Amgen, Inc.: Revenue ($m), AGR (%), 2014-2018
Table 14.17 Merck & Co., Inc.: Overview, 2019
Table 14.18 Merck & Co., Inc.: Revenue ($m), AGR (%), 2014-2018
Table 14.19 Bayer AG: Overview, 2019
Table 14.20 Bayer AG: Revenue ($m), AGR (%), 2014-2018
Table 14.21 Celgene Corporation: Overview, 2019
Table 14.22 Celgene Corporation: Revenue ($m), AGR (%), 2014-2018
Table 14.23 Bausch Health Companies Inc.: Overview, 2019
Table 14.24 Bausch Health Companies Inc.: Revenue ($m), AGR (%), 2014-2018
Table 14.25 Bristol-Myers Squibb Company: Overview, 2019
Table 14.26 Bristol-Myers Squibb Company: Revenue ($m), AGR (%), 2014-2018
Table 14.27 AbbVie Inc.: Overview, 2019
Table 14.28 Allergan plc: Revenue ($m), AGR (%), 2014-2018
Table 14.29 Eli Lilly and Company: Overview, 2019
Table 14.30 Eli Lilly and Company: Revenue ($m), AGR (%), 2014-2018
Table 15.1 Psoriasis Drugs Pipeline: Phase 3 Drugs, 2019
Table 15.2 Psoriasis Drugs Pipeline: Phase 2 Drugs, 2018
Table 15.3 Psoriasis Drugs Pipeline: Phase 1 Drugs, 2018
Table 15.4 Skin Infections Drugs Pipeline: Phase 3 Drugs, 2019
Table 15.5 Skin Infections Drugs Pipeline: Phase 2 Drugs, 2019
Table 15.6 Acne Drugs Pipeline: Phase 3 Drugs, 2019
Table 15.7 Acne Drugs Pipeline: Phase 2 Drugs, 2019
Table 15.8 Dermatitis Drugs Pipeline: Phase 3 Drugs, 2019
Table 15.9 Dermatitis Drugs Pipeline: Phase 2 Drugs, 2019
Table 15.10 Other Dermatological Drugs Pipeline: Filed or Recently Launched Drugs, 2019
Table 15.11 Other Dermatological Drugs Pipeline: Phase 3 Drugs, 2019
Table 15.12 Dermatitis Drugs Pipeline: Phase 2 Drugs, 2019
Table 16.1 SWOT Analysis of the Global Dermatological Drugs Market, 2020-2030
Table 17.1 Global Dermatological Drugs Market Forecast: Revenue ($bn), and CAGR (%), 2019, 2025 and 2030
Table 17.2 Global Dermatological Drugs Market by Indication: Revenue ($bn), and Market Share (%), 2019
Table 17.3 Global Dermatological Drugs Market by Region: Revenue ($bn), 2019, 2025, 2030
Table 17.4 Global Dermatological Drugs Market by Indication: Revenue ($Bn), 2020, 2025, 2030
List of Figures
Figure 1.1 Global Dermatological Drugs Market Segmentation Overview
Figure 2.1 Anatomy of Human Skin
Figure 3.1 Global Dermatological Drugs Market by Indication: Market Share (%), 2019
Figure 3.2 World Dermatological Drugs Market: Revenues ($bn), by Indication, 2019
Figure 3.3 Global Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%), 2019-2030
Figure 3.4 The Global Dermatological Drugs Market Forecast by Indication: AGR (%), 2020-2025
Figure 3.5 The Global Dermatological Drugs Market Forecast by Indication: AGR (%), 2025-2030
Figure 3.6 The Global Dermatological Drugs Market Forecast by Indication: AGR(%) 2020-2030
Figure 3.7 Global Dermatological Drugs Market by Indication: Market Share (%), 2020
Figure 3.8 Global Dermatological Drugs Market by Indication: Market Share (%), 2025
Figure 3.9 Global Dermatological Drugs Market by Indication: Market Share (%), 2030
Figure 4.1 World Psoriasis Drugs Market: Revenues ($bn), by Drugs, 2019
Figure 4.2 Global Psoriasis Drugs Segment Forecast: Revenue ($bn) AGR (%), 2019-2030
Figure 4.3 Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2019
Figure 4.4 Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2025
Figure 4.5 Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2030
Figure 4.6 Global Humira Market Forecast: Revenue ($bn) AGR (%), 2010-2017
Figure 4.7 Global Humira Market Forecast: Revenue ($bn) AGR (%), 2019-2030
Figure 4.8 Global Stelara Market Forecast: Revenue ($bn) AGR (%), 2010-2017
Figure 4.9 Global Stelara Market Forecast: Revenue ($bn) AGR (%), 2019-2030
Figure 4.10 Global Enbrel Market Forecast: Revenue ($bn) AGR (%), 2009-2017
Figure 4.11 Global Enbrel Market Forecast: Revenue ($bn) AGR (%), 2019-2030
Figure 4.12 Global Remicade Market Forecast: Revenue ($bn) AGR (%), 2009-2017
Figure 4.13 Global Remicade Market Forecast: Revenue ($bn) AGR (%), 2019-2030
Figure 4.14 Global Taltz Market Forecast: Revenue ($bn) AGR (%), 2019-2030
Figure 4.15 Global Otezla Market Forecast: Revenue ($bn) AGR (%), 2019-2030
Figure 4.16 Global Cosentyx Market Forecast: Revenue ($bn) AGR (%), 2019-2030
Figure 4.17 Global Others Market Forecast: Revenue ($bn) AGR (%), 2019-2030
Figure 5.1 World Skin Infection Drugs Market: Revenues ($bn), by Drugs, 2019
Figure 5.2 Global Skin Infection Drugs Segment Forecast: Revenue ($bn) AGR (%), 2019-2030
Figure 5.3 The Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2019
Figure 5.4 The Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2025
Figure 5.5 The Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2030
Figure 5.6 Global Cubicin Market Forecast: Revenue ($bn) AGR (%), 2019-2030
Figure 5.7 Global Zyvox Market Forecast: Revenue ($bn) AGR (%), 2010-2017
Figure 5.8 Global Zyvox Market Forecast: Revenue ($bn) AGR (%), 2019-2030
Figure 5.9 Global Canesten Market Forecast: Revenue ($bn) AGR (%), 2011-2017
Figure 5.10 Global Canesten Market Forecast: Revenue ($Bn) AGR (%), 2019-2030
Figure 5.11 Global Valtrex Market Forecast: Revenue ($bn) AGR (%), 2010-2017
Figure 5.12 Global Valtrex Market Forecast: Revenue ($bn) AGR (%), 2019-2030
Figure 5.13 Global Sivexto Market Forecast: Revenue ($bn) AGR (%), 2019-2030
Figure 5.14 Global Lamisil Market Forecast: Revenue ($bn) AGR (%), 2019-2030
Figure 5.15 Global Others Market Forecast: Revenue ($bn) AGR (%), 2019-2030
Figure 6.1 World Acne Drugs Market: Revenues ($bn), by Drugs, 2019
Figure 6.2 Global Acne Drugs Segment Forecast: Revenue ($bn) AGR (%), 2019-2030
Figure 6.3 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2019
Figure 6.4 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2025
Figure 6.5 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2030
Figure 6.6 Global Epiduo Market Forecast: Revenue ($bn) AGR (%), 2019-2030
Figure 6.7 Global Solodyn Market Forecast: Revenue ($bn) AGR (%), 2019-2030
Figure 6.8 Global Claravis Market Forecast: Revenue ($bn) AGR (%), 2019-2030
Figure 6.9 Global Aczone Market Forecast: Revenue ($bn) AGR (%), 2019-2030
Figure 6.10 Global Retin-A Micro Market Forecast: Revenue ($bn) AGR (%), 2019-2030
Figure 6.11 Global Absorica/ Epirus Market Forecast: Revenue ($bn) AGR (%), 2019-2030
Figure 6.12 Global Ziana Market Forecast: Revenue ($bn) AGR (%), 2019-2030
Figure 6.13 Global Acanya/Onexton Market Forecast: Revenue ($bn) AGR (%), 2019-2030
Figure 6.14 Global Others Market Forecast: Revenue ($bn) AGR (%), 2019-2030
Figure 7.1 World Dermatitis Drugs Market: Revenues ($bn), by Drugs, 2019
Figure 7.2 Global Dermatitis Drugs Segment Forecast: Revenue ($bn) AGR (%), 2019-2030
Figure 7.3 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2019
Figure 7.4 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2025
Figure 7.5 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2030
Figure 7.6 Global Bepanthen/ Bepanthol Market Forecast: Revenue ($bn), AGR (%), 2019-2030
Figure 7.7 Global Elocon Market Forecast: Revenue ($bn) AGR (%), 2019-2030
Figure 7.8 Global Protopic Market Forecast: Revenue ($bn) AGR (%), 2019-2030
Figure 7.9 Global Dermovate Market Forecast: Revenue ($bn) AGR (%), 2019-2030
Figure 7.10 Global Other Dermatitis Market Forecast: Revenue ($bn) AGR (%), 2019-2030
Figure 8.1 World Dermatological Drugs Market: Revenues ($bn) by Region, 2019
Figure 8.2 World Dermatological Drugs Market: Revenues ($bn) by Region, 2030
Figure 8.3 Global Dermatological Drugs Market Forecast By Region: Revenue ($bn), 2019-2030
Figure 8.4 World Dermatological Drugs Market: Market Shares (%) by Regional Market, 2020
Figure 8.5 World Dermatological Drugs Market: Market Shares (%) by Regional Market, 2025
Figure 8.6 World Dermatological Drugs Market: Market Shares (%) by Regional Market, 2030
Figure 9.1 North America Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
Figure 9.2 North America Dermatological Drugs Market: Market Shares (%) by Country, 2019
Figure 9.3 North America Dermatological Drugs Market: Market Shares (%) by Country, 2025
Figure 9.4 North America Dermatological Drugs Market: Market Shares (%) by Country, 2030
Figure 9.5 U.S. Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
Figure 9.6 Canada Dermatological Drugs Market Forecast: Revenues ($ Bn), AGR (%), 2019-2030
Figure 10.1 Europe Dermatological Drugs Market: Revenues ($bn) by Country/Sub-region, 2019
Figure 10.2 Europe Dermatological Drugs Market Forecast: Revenues ($ bn), AGR (%), 2019-2030
Figure 10.3 Europe Dermatological Drugs Market: Market Shares (%) by Regional Market, 2019
Figure 10.4 Europe Dermatological Drugs Market: Market Shares (%) by Country Market, 2025
Figure 10.5 Europe Dermatological Drugs Market: Market Shares (%) by Country Market, 2030
Figure 10.6 Germany Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
Figure 10.7 France Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
Figure 10.8 U.K. Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
Figure 10.9 Italy Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
Figure 10.10 Spain Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
Figure 10.11 Rest of Europe Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
Figure 11.1 Asia-Pacific Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
Figure 11.2 Asia-Pacific Dermatological Drugs Market: Market Shares (%) by Country, 2019
Figure 11.3 Asia-Pacific Dermatological Drugs Market: Market Shares (%) by Country, 2025
Figure 11.4 Asia-Pacific Dermatological Drugs Market: Market Shares (%) by Country, 2030
Figure 11.5 China Dermatological Drugs Market Forecast: Revenues ($ bn), AGR (%), 2019-2030
Figure 11.6 Japan Dermatological Drugs Market Forecast: Revenues ($ bn), AGR (%), 2019-2030
Figure 11.7 India Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
Figure 11.8 Rest of Asia-Pacific Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
Figure 12.1 Latin America Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
Figure 12.2 Latin America Dermatological Drugs Market: Market Shares (%) by Country Market, 2019
Figure 12.3 Latin America Dermatological Drugs Market: Market Shares (%) by Country Market, 2025
Figure 12.4 Latin America Dermatological Drugs Market: Market Shares (%) by Country Market, 2030
Figure 12.5 Brazil Dermatological Drugs Market Forecast: Revenues ($ bn), AGR (%), 2019-2030
Figure 12.6 Mexico Dermatological Drugs Market Forecast: Revenues ($ bn), AGR (%), 2019-2030
Figure 12.7 Rest of Latin America Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
Figure 13.1 Middle East & Africa (MEA) Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
Figure 13.2 Middle East & Africa Dermatological Drugs Market: Market Shares (%) by Country Market, 2019
Figure 13.3 Middle East & Africa Dermatological Drugs Market: Market Shares (%) by Country Market, 2025
Figure 13.4 Middle East & Africa Dermatological Drugs Market: Market Shares (%) by Country Market, 2030
Figure 13.5 Saudi Arabia Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
Figure 13.6 South Africa Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
Figure 13.7 Rest of MEA Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030
Figure 14.1 Johnson & Johnson: Revenue ($m), AGR (%), 2013-2017
Figure 14.2 Johnson & Johnson: Business Segment Revenue Share (%), 2018
Figure 14.3 Johnson & Johnson: Region Revenue Share (%), 2018
Figure 14.4 GlaxoSmithKline plc: Revenue ($m), 2014-2018
Figure 14.5 GlaxoSmithKline plc: Business Segment Revenue Share (%), 2018
Figure 14.6 GlaxoSmithKline plc: Pharmaceutical Business Segment Revenue Share (%), 2018
Figure 14.7 GlaxoSmithKline plc: by Region Revenue Share (%), 2018
Figure 14.8 Pfizer, Inc.: Revenue ($bn), Net Income (Sbn), R&D Investment ($bn), 2019-2018
Figure 14.9 Pfizer, Inc.: Business Segment Revenue Share (%), 2018
Figure 14.10 Pfizer, Inc.: National Revenue Share (%), 2018
Figure 14.11 LEO Pharma A/S : Revenue ($m), AGR (%), 2014-2018
Figure 14.12 LEO Pharma A/S: Therapeutic Area Revenue Share (%), 2018
Figure 14.13 LEO Pharma A/S: Region Revenue Share (%), 2018
Figure 14.14 AbbVie Inc.: Revenue ($m), AGR (%), 2014-2018
Figure 14.15 AbbVie Inc.: Regional Segment Revenue Share (%), 2018
Figure 14.16 Novartis: Revenue ($m), AGR (%), 2014-2018
Figure 14.17 Novartis: Revenue, by Division, Share (%), 2018
Figure 14.18 Novartis: Revenue, by Region, Share (%), 2018
Figure 14.19 Amgen, Inc.: Revenue ($m), AGR (%), 2014-2018
Figure 14.20 Amgen, Inc.: Revenue, by Division, Share (%), 2018
Figure 14.21 Amgen, Inc.: Revenue, by Region, Share (%), 2019
Figure 14.22 Merck & Co., Inc.: Revenue ($m), AGR (%), 2014-2018
Figure 14.23 Merck & Co., Inc.: Business Segment Revenue Share (%), 2018
Figure 14.24 Merck & Co., Inc.: Region Revenue Share (%), 2018
Figure 14.25 Bayer AG: Revenue ($m), AGR (%), 2014-2018
Figure 14.26 Bayer AG: Business Segment Revenue Share (%), 2018
Figure 14.27 Bayer AG: Region Revenue Share (%), 2018
Figure 14.28 Celgene Corporation: Revenue ($m), AGR (%), 2014-2018
Figure 14.29 Celgene Corporation: Regional Segment Revenue Share (%), 2018
Figure 14.30 Bausch Health Companies Inc.: Revenue ($m), AGR (%), 2014-2018
Figure 14.31 Bausch Health Companies Inc.: Regional Segment Revenue Share (%), 2018
Figure 14.32 Bristol-Myers Squibb Company: Revenue ($m), AGR (%), 2014-2018
Figure 14.33 Bristol-Myers Squibb Company: Regional Segment Revenue Share (%), 2018
Figure 14.34 Allergan plc: Revenue ($m), AGR (%), 2014-2018
Figure 14.35 Allergan plc: Regional Segment Revenue Share (%), 2018
Figure 14.36 Eli Lilly and Company: Revenue, Net Income, and R&D Investment ($m), 2014-2018
Figure 14.37 Eli Lilly and Company: Regional Segment Revenue Share (%), 2018
Figure 16.1 Porter‟s Five Force Analysis
Figure 17.1 Global Dermatological Drugs Market Forecast: Revenue ($bn) 2017, 2025, 2030
Figure 17.2 World Dermatological Drugs Market: Revenues ($bn), by Indication, 2019
Figure 17.3 The Global Dermatological Drugs Market Forecast by Region: Revenue ($bn), 2019, 2025, 2030
Figure 17.4 The Global Dermatological Drugs Market Forecast by Region: Revenue ($bn), 2019, 2025, 2030
Abbott
AbbVie
Actavis
AET BioTech
Alkem Laboratories
Allergan
Almirall
Amgen
Anacor
Ascend Therapeutics
Astellas
Aurovindo
Barr Labs
Bayer
Betta Pharmaceuticals
Biocon/Mylan
Biofrontera
Biogen
Biovail Laboratories
BioXpress Therapeutics
Boehringer Ingelheim
Bristol-Myers Squibb
Brazilian Society of Dermatology
Cadila Healthcare
Calico
Can-Fite BioPharma
Cassiopea SpA
Celgene
Celltrion
Cempra
Cipher Pharmaceuticals
Cipla
Colorescience
Cubist Pharmaceuticals
Cutanea Life Sciences
Dow Pharmaceuticals Science
Dr Reddy’s
Durata Therapeutics
Eisai
Eli Lilly
European Medicines Agency (EMA)
European Pharmaceutical Market Research Association (EPhMRA)
FibroTx
Food and Drug Association (FDA)
Foamix
Fougera
Fujifilm
Galapagos NV
G&E Herbal Biotechnology
Galderma
GlaxoSmithKline
Glenmark Pharmaceuticals
Heritage
Impax
Incyte
International Health Partners
Janssen Biotech
Johnson & Johnson
Kyowa Hakko Kirin
L’Oreal
LEO Pharma
Lupin
Maruho
Mayne Pharma
Medicis
Medison Pharma
Melinta Pharmaceuticals
Merck
Merz Pharmaceuticals
Mitsubishi Tanabe
MorphoSys
Mylan
NanoBio Corporation
National Psoriasis Foundation (NPF)
NeoStrata Compnay Inc
Nestle Skin Health
Novan
Novartis
Perriogo
Pfizer
PharmaPraxis
Photocure
Pierre Fabre
Provectus Biopharmaceuticals
QLT Inc
Ranbaxy
Regeneron Pharmaceuticals
Roche
Samsung Bioepis
Samsung BioLogics
Sandoz
Sanofi
Schering-Plough
Shanghai CP Buojian Pharmaceutical
Sidmak Labs
Sol-Gel Technologies Ltd
Sun Pharma
Sunovion
Takeda
Tanabe
Tanja Todberg
Taro Pharmaceuticals
Teva
Thesan Pharmaceuticals Inc
Topica Pharmaceuticals
UCB
Valeant
Vical
Warner Chilcott
Watson Pharmaceuticals
Xenon Pharmaceuticals
Ziarco Group Limited
Zydus
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
